The 12-year-old company had been collaborating with British pharmaceutical giant GlaxoSmithKline on an immuno-oncology drug ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

“Lots of companies are limping along,” said Mani Foroohar, senior research analyst at Boston health care investment bank Leerink Partners. Foroohar, a top biotech analyst, has slapped an ...

A few weeks after releasing disappointing data from its norovirus vaccine trial, a Boston biotech is cutting its workforce. A few weeks after releasing disappointing data from its norovirus ...

A Nurturing Force in Boston's Biotech Ecosystem Cambridge Scientific has emerged as a trusted partner in the region's booming biotech industry. Founded in 1997 by CEO Barb Pearlman, the company's ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

An international pharmaceutical research company will lay off 83 Boston-area employees by the end of June, according to new filings with the state. Ono Pharma, the United States subsidiary of a ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

even as neighborhoods like Allston and Boston suburbs see an uptick in biotech companies. Early stage innovation, development, and experimentation is being increasingly outsourced to startups like ...

In August, a single email triggered a chain of hand-wringing and strategizing inside one of America’s largest medical technology companies: A reporter asked Boston Scientific if the biotech ...